Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Potential transmission of HBV, HCV and HIV infections in nail salons and barbershops

The risk of hepatitis transmission through non-single use instruments -- such as nail files, nail brushes, finger bowls, foot basins, buffers, razors, clippers, and scissors -- during nail salon and barbershop visits cannot be excluded, according to the results of a new report unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

1 Nov 2011

Gilead, Bristol-Myers Squibb to develop and commercialize fixed-dose combination for HIV

Bristol-Myers Squibb Company and Gilead Sciences, Inc. today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor REYATAZ (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.

27 Oct 2011

Three dry days a week reduces risk of alcohol related liver disease

The Royal College of Physicians said the present official guidance on healthy drinking limits is ‘extremely dangerous’ and must be rewritten – because it implies that drinking every day is fine. Government advice states men should drink no more than four units a day and women no more than three.

24 Oct 2011

CryoLife begins enrollment in BioFoam Surgical Matrix IDE clinical trial

CryoLife, Inc.,, a leading tissue processing and medical device Company focused on cardiac and vascular surgery, today announced that it has enrolled the first patient in its U.S. Investigational Device Exemption (IDE) clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology. In connection with the trial, BioFoam will be used as an adjunct to conservative measures of achieving hemostasis on newly resected liver parenchyma.

24 Oct 2011

Vertex initiates INCIVEK combination Phase 3b study for hepatitis C

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called CONCISE that will evaluate the potential for treatment with INCIVEK (telaprevir) combination therapy to be shortened to 12 weeks in people with genotype 1 chronic hepatitis C who have the 'CC' variation near the IL28B gene.

24 Oct 2011

Boehringer Ingelheim announces new data from hepatitis C virus portfolio

Boehringer Ingelheim announced today that new data from its hepatitis C virus (HCV) portfolio will be presented in scientific sessions at The Liver Meeting 2011, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 4 - November 8 in San Francisco, CA.

22 Oct 2011

RCSI study: Alpha-1 antitrypsin deficiency more prevalent in Ireland

Researchers from the Royal College of Surgeons in Ireland (RCSI), Beaumont Hospital, and Trinity College Dublin have conducted a study which has found that Ireland has one of the highest incidences in the world of a genetic condition that causes severe hereditary emphysema.

20 Oct 2011

Acute HCV screening strategy for HIV-infected individuals

Researchers at The Miriam Hospital demonstrated a practical strategy for regularly screening HIV-infected patients for acute hepatitis C virus infection (HCV), a "silent epidemic" that is rising undetected in this population and can lead to serious health complications.

19 Oct 2011

Differences in key metabolic enzyme levels linked to liver damage susceptibility

Differences in the levels of two key metabolic enzymes may explain why some people are more susceptible to liver damage, according to a study in the October 17 issue of The Journal of Cell Biology (www.jcb.org).

18 Oct 2011

NIH awards Einstein College of Medicine $5.7M for children's IDD Research Center

The Eunice Kennedy Shriver National Institute for Child Health and Human Development, part of the National Institutes of Health, has awarded researchers at Albert Einstein College of Medicine of Yeshiva University $5.7 million to fund the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center (IDDRC).

18 Oct 2011

ApoPharma receives FDA approval for Ferriprox to treat transfusional iron overload

The U.S. Food and Drug Administration today approved Ferriprox (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.

15 Oct 2011

New technique stimulates stem cells after liver transplant to prevent rejection

Johns Hopkins researchers have developed a way to stimulate a rat's stem cells after a liver transplant as a means of preventing rejection of the new organ without the need for lifelong immunosuppressant drugs.

14 Oct 2011

Skin cell to liver cell shows promise for genetic liver disease

In a new scientific breakthrough, researchers have taken skin cells from a patient with liver disease and turned them into replacement liver cells. Although the procedure is years before it can be used in humans, but if approved, it could launch a new era of personalized therapies for serious genetic disorders.

13 Oct 2011

Isis designates ISIS-AATRx candidate in collaboration with GSK

Isis Pharmaceuticals, Inc. announced today that it has designated the second development candidate, ISIS-AATRx, in its collaboration with GlaxoSmithKline

12 Oct 2011

CHOP, Albert Einstein College of Medicine to study genetics of conotruncal defects

The Eunice Kennedy Shriver National Institute of Child Health & Human Development, part of the National Institutes of Health, has awarded researchers at Albert Einstein College of Medicine of Yeshiva University and collaborators at the Children's Hospital of Philadelphia (CHOP) a five-year, $6.7 million grant to study the genetics of both rare and common congenital heart abnormalities known as conotruncal defects.

12 Oct 2011

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

11 Oct 2011

VGX International, Inovio partner to co-develop SynCon vaccines for hepatitis B and C infections

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc., to co-develop Inovio's SynCon therapeutic vaccines for hepatitis B and C infections.

10 Oct 2011

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.

10 Oct 2011

Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA and mRNA-targeted therapies, today announced the Company will report new clinical data results from the miravirsen Phase 2a proof-of-concept study to treat patients infected with the Hepatitis C virus (HCV) in a late-breaking oral presentation session at the American Association for the Study of Liver Diseases (AASLD) 2011 annual meeting.

4 Oct 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers Squibb Company announced today that 22 abstracts on the Company's research in liver disease have been accepted for presentation at The Liver Meeting 2011, the 62nd annual meeting of the American Association for the Study of Liver Diseases, in San Francisco, November 4 - 8.

1 Oct 2011

Liver Disease News and Research

Further Reading

Potential transmission of HBV, HCV and HIV infections in nail salons and barbershops

Gilead, Bristol-Myers Squibb to develop and commercialize fixed-dose combination for HIV

Three dry days a week reduces risk of alcohol related liver disease

CryoLife begins enrollment in BioFoam Surgical Matrix IDE clinical trial

Vertex initiates INCIVEK combination Phase 3b study for hepatitis C

Boehringer Ingelheim announces new data from hepatitis C virus portfolio

RCSI study: Alpha-1 antitrypsin deficiency more prevalent in Ireland

Acute HCV screening strategy for HIV-infected individuals

Differences in key metabolic enzyme levels linked to liver damage susceptibility

NIH awards Einstein College of Medicine $5.7M for children's IDD Research Center

ApoPharma receives FDA approval for Ferriprox to treat transfusional iron overload

New technique stimulates stem cells after liver transplant to prevent rejection

Skin cell to liver cell shows promise for genetic liver disease

Isis designates ISIS-AATRx candidate in collaboration with GSK

CHOP, Albert Einstein College of Medicine to study genetics of conotruncal defects

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

VGX International, Inovio partner to co-develop SynCon vaccines for hepatitis B and C infections

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Santaris Pharma to report new clinical data from miravirsen Phase 2a study on HCV

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News